ResearcherNanjing University of Chinese MedicineNo recent work listed

Meijuan Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2003-5679; OpenAlex author ID A5101848536. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper

Papers 2

Agrimoniin is a dual inhibitor of AKT and ERK pathways that inhibit pancreatic cancer cell proliferation. Last author DOI 10.1002/ptr.7867 ↗
Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor rec… Co-author DOI 10.1007/s10787-021-00848-1 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiong-Fei Zhang · 1 shared paper, 2023 · strength 0.17
- Paper Agrimoniin is a dual inhibitor of AKT and ERK pathways that inhibit pancreatic cancer cell proliferation. DOI 10.1002/ptr.7867 ↗
Cunsi Shen · 1 shared paper, 2021 · strength 0.16
- Paper Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling… DOI 10.1007/s10787-021-00848-1 ↗
Zhengguang Zhang · 1 shared paper, 2021 · strength 0.16
- Paper Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling… DOI 10.1007/s10787-021-00848-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.